Assessing the influence of circulating tumor cells on the prognosis of breast cancer

Aim. To monitor antitumor therapy using the level of circulating tumor cells (CTC) in the peripheral blood of breast cancer (BC) patients using aptamers.Materials and methods. The study included 34 patients with BC. The primary determination of CTC content was performed before surgical treatment in...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Zyuzyukina, V. I. Borodulina, O. S. Kolovskaya, G. S. Zamay, D. A. Kirichenko, T. N. Zamay, A. S. Kichkaylo, R. A. Zukov
Format: Article
Language:Russian
Published: ABV-press 2025-03-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/1313
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849241520178200576
author A. V. Zyuzyukina
V. I. Borodulina
O. S. Kolovskaya
G. S. Zamay
D. A. Kirichenko
T. N. Zamay
A. S. Kichkaylo
R. A. Zukov
author_facet A. V. Zyuzyukina
V. I. Borodulina
O. S. Kolovskaya
G. S. Zamay
D. A. Kirichenko
T. N. Zamay
A. S. Kichkaylo
R. A. Zukov
author_sort A. V. Zyuzyukina
collection DOAJ
description Aim. To monitor antitumor therapy using the level of circulating tumor cells (CTC) in the peripheral blood of breast cancer (BC) patients using aptamers.Materials and methods. The study included 34 patients with BC. The primary determination of CTC content was performed before surgical treatment in 2017. 32 and 48 months after surgical treatment, the number of CTC and their derivatives was re-determined to assess the dynamics of the disease. Detection of CTC was carried out in 3.5 ml of blood from BC patients using the aptamer MDA231, which is affinity for BC cells and labeled with the fluorescent dye Cy5. Counting of CTC in smears of blood samples was performed using fluorescence and scanning laser microscopy.Results. The observation period for patients ranged from 1 to 143 months. 7 (20.6 %) of 34 patients experienced disease progression. The median time to disease relapse was 69 months. A statistically significant inverse moderate correlation (p <0.05) was revealed between age and the number of CTC (–0.39). A statistically significant direct average correlation (p <0.05) between proliferative activity index Ki-67 and the number of CTC (0.42) was also found. Statistically significant differences were found between patients divided into two groups depending on the presence or absence of CTC in the time until the onset of disease relapse (p = 0.015). The median survival and interquartile range in patients with CTC was 68 (23–70) months, and in patients without CTC 76 (58–108) months.Conclusion. The risk of developing BC relapse with positive detection of CTC is 28.6 %. The value of the absolute risk indicator in BC patients without CTC in the peripheral blood is 5.9 %. The value of the relative risk indicator is 4.857.
format Article
id doaj-art-ed5b92a0e9b44fc58d723dcd9d5a8eee
institution Kabale University
issn 1994-4098
1999-8627
language Russian
publishDate 2025-03-01
publisher ABV-press
record_format Article
series Опухоли женской репродуктивной системы
spelling doaj-art-ed5b92a0e9b44fc58d723dcd9d5a8eee2025-08-20T04:00:08ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272025-03-01204142010.17650/1994-4098-2024-20-4-14-20873Assessing the influence of circulating tumor cells on the prognosis of breast cancerA. V. Zyuzyukina0V. I. Borodulina1O. S. Kolovskaya2G. S. Zamay3D. A. Kirichenko4T. N. Zamay5A. S. Kichkaylo6R. A. Zukov7Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Ministry of Health of Russia; Krasnoyarsk Regional Clinical Cancer Center named after A.I. KryzhanovskyKrasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Ministry of Health of RussiaKrasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Ministry of Health of Russia; Federal Research Center Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of SciencesKrasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Ministry of Health of Russia; Federal Research Center Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of SciencesKrasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Ministry of Health of RussiaKrasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Ministry of Health of Russia; Federal Research Center Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of SciencesKrasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Ministry of Health of Russia; Federal Research Center Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of SciencesKrasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Ministry of Health of Russia; Krasnoyarsk Regional Clinical Cancer Center named after A.I. KryzhanovskyAim. To monitor antitumor therapy using the level of circulating tumor cells (CTC) in the peripheral blood of breast cancer (BC) patients using aptamers.Materials and methods. The study included 34 patients with BC. The primary determination of CTC content was performed before surgical treatment in 2017. 32 and 48 months after surgical treatment, the number of CTC and their derivatives was re-determined to assess the dynamics of the disease. Detection of CTC was carried out in 3.5 ml of blood from BC patients using the aptamer MDA231, which is affinity for BC cells and labeled with the fluorescent dye Cy5. Counting of CTC in smears of blood samples was performed using fluorescence and scanning laser microscopy.Results. The observation period for patients ranged from 1 to 143 months. 7 (20.6 %) of 34 patients experienced disease progression. The median time to disease relapse was 69 months. A statistically significant inverse moderate correlation (p <0.05) was revealed between age and the number of CTC (–0.39). A statistically significant direct average correlation (p <0.05) between proliferative activity index Ki-67 and the number of CTC (0.42) was also found. Statistically significant differences were found between patients divided into two groups depending on the presence or absence of CTC in the time until the onset of disease relapse (p = 0.015). The median survival and interquartile range in patients with CTC was 68 (23–70) months, and in patients without CTC 76 (58–108) months.Conclusion. The risk of developing BC relapse with positive detection of CTC is 28.6 %. The value of the absolute risk indicator in BC patients without CTC in the peripheral blood is 5.9 %. The value of the relative risk indicator is 4.857.https://ojrs.abvpress.ru/ojrs/article/view/1313breast cancerrelapsemonitoring of antitumor therapycirculating tumor cells
spellingShingle A. V. Zyuzyukina
V. I. Borodulina
O. S. Kolovskaya
G. S. Zamay
D. A. Kirichenko
T. N. Zamay
A. S. Kichkaylo
R. A. Zukov
Assessing the influence of circulating tumor cells on the prognosis of breast cancer
Опухоли женской репродуктивной системы
breast cancer
relapse
monitoring of antitumor therapy
circulating tumor cells
title Assessing the influence of circulating tumor cells on the prognosis of breast cancer
title_full Assessing the influence of circulating tumor cells on the prognosis of breast cancer
title_fullStr Assessing the influence of circulating tumor cells on the prognosis of breast cancer
title_full_unstemmed Assessing the influence of circulating tumor cells on the prognosis of breast cancer
title_short Assessing the influence of circulating tumor cells on the prognosis of breast cancer
title_sort assessing the influence of circulating tumor cells on the prognosis of breast cancer
topic breast cancer
relapse
monitoring of antitumor therapy
circulating tumor cells
url https://ojrs.abvpress.ru/ojrs/article/view/1313
work_keys_str_mv AT avzyuzyukina assessingtheinfluenceofcirculatingtumorcellsontheprognosisofbreastcancer
AT viborodulina assessingtheinfluenceofcirculatingtumorcellsontheprognosisofbreastcancer
AT oskolovskaya assessingtheinfluenceofcirculatingtumorcellsontheprognosisofbreastcancer
AT gszamay assessingtheinfluenceofcirculatingtumorcellsontheprognosisofbreastcancer
AT dakirichenko assessingtheinfluenceofcirculatingtumorcellsontheprognosisofbreastcancer
AT tnzamay assessingtheinfluenceofcirculatingtumorcellsontheprognosisofbreastcancer
AT askichkaylo assessingtheinfluenceofcirculatingtumorcellsontheprognosisofbreastcancer
AT razukov assessingtheinfluenceofcirculatingtumorcellsontheprognosisofbreastcancer